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IntroductIon
According to the Journal of Gene Medicine there are 246 clini-
cal trials worldwide investigating naked plasmid DNA (www.
wiley.co.uk/genmed/clinical), representing almost 20% of all 
vectors used in clinical trials and coming in third place behind 
adenovirus (24.8%) and retrovirus (22.3%) vectors. The devel-
opment of novel nonviral vaccines and therapeutics for the 
prevention or treatment of disease has warranted the develop-
ment of a delivery system that enables satisfactory expression 
of the desired molecule. Viral transfection systems have classi-
cally resulted in high expression levels of transgene products; 
however, this approach has immunological drawbacks1 and 
has led to nonviral vectors increasingly becoming the vehicle 
of choice. To boost efficacy of nonviral gene therapies several 
delivery  methods have been under investigation such as lipid-
mediated entry into cells,2 jet  injection, gene gun delivery,3 and 
sonoporation.4 In this review we will focus on electroporation 
(EP) whereby  cellular membranes are transiently destabilized 
by localized and controlled electric fields, facilitating the entry 
of foreign molecules into cells and tissues.5 Although the exact 
mechanism of cellular macromolecule entry is still under dis-
cussion, entry of small molecules such as anticancer drugs 
seems to occur by simple diffusion after the pulse, and larger 
molecules such as plasmid DNA are thought to enter through 
a multistep mechanism involving the interaction of the DNA 
molecule with the destabilized membrane during the pulse and 
then its passage across the membrane.6
The technique of EP has been used for over 25 years as a 
means of introducing macromolecules, including DNA, into 
cells in vitro,7 and is now widely used for transfection of plas-
mids into different tissues in vivo.8 More recently, EP has been 
used for the application of DNA vaccines and gene therapies. 
However, the transition of EP to the clinical setting has been 
slow to progress. Initially, the administration of bleomycin, an 
anticancer agent that induces DNA strand breaks, in combina-
tion with EP was the subject of numerous preclinical studies 
(reviewed in ref. 9) and tested in several humans with the first 
clinical trials started >15 years ago.10,11 Of note, pivotal stud-
ies performed around the same time demonstrated for the first 
time effective macromolecule in vivo EP in tumors,12 liver,13,14 
and skeletal muscle.15
Although other physical delivery methods, such as ultra-
sound, have been used recently in small animal settings,16 
 successful small and large animal including nonhuman primate 
studies and human clinical trials using EP have demonstrated 
the effectiveness of this technique with plasmids. Overall, the 
technique of EP has been shown to be a versatile approach, as 
delivery has been accomplished across several species, different 
types of cells and tissues, EP conditions, macromolecule types, 
and most importantly, a large spectrum of applications. Several 
clinical trials are now investigating EP as a medical technology 
in humans, as shown in Figure 1.
Various well-designed preclinical studies have been stepping 
stones in the progression to clinics (reviewed in refs 17–20). 
While diverse in scope and approaches, the ability to provide 
sound evidence and preliminary findings in laboratory or 
companion animals have proven crucial for the design of suc-
cessful clinical trials. Furthermore, the development of naked 
DNA and EP technology in animals not only provides the 
basis for human studies but also lays the foundation for vet-
erinary  medical advances and bridges the gap between the two 
disciplines.21–25 The preclinical studies that have led to the 
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The use of recombinant cytokines has provided a glimmer of 
hope in the fight against cancer; however, the frequent systemic 
administration of high doses often leads to dose-limiting side 
effects and toxicity.26 Therefore, new treatment strategies are in 
high demand. Interleukin (IL)-2 and IL-12 have shown  promising 
antitumor effects in numerous preclinical studies by improving 
immune responses although the exact mechanism has yet to be 
elucidated.27–29
Previous studies have examined the treatment of mice  bearing 
murine ovarian teratocarcinoma with IL plasmid DNA com-
plexed with a cationic lipid.30 The administration of IL-2 pDNA 
increased the local concentration of the expressed cytokine and 
extended the length of expression from 24 hours for the recom-
binant form to up to 10 days for the plasmid DNA. Furthermore, 
the results showed that there was a significant antitumor effect as 
well as a significant increase in survival. Combining the delivery 
of bleomycin with IL-2 plasmid using EP resulted in long-term 
disease free survival in a mouse melanoma model.31
Nonclinical investigational new drug (IND) application-
 enabling studies in mice evaluated the effect of intratumoral 
murine IL-2 pDNA on local expression and systemic distribution 
of IL-2 transgene, as well as the inhibition of established tumor 
growth.32 Results showed that EP-assisted delivery produced the 
highest levels of IL-2 in the tumor (3–7 times higher than without 
EP). Local sustained levels of IL-2 within the tumor and relatively 
low, short-lived serum levels were detected. Tumor regression was 
noted with IL-2 plus EP compared to IL-2 alone. Further studies 
testing the safety of repeated s.c. administrations of VCL-IM01 
[human IL-2 pDNA (VCL-1102) in PBS] with EP were carried 
out in rats. There were no mortalities, no evidence of drug-related 
toxicity, no erythema associated with injection or EP, and overall 
treatment was well tolerated. These preclinical findings, in combi-
nation with previously published safety study results for VCL-1102 
pDNA,33 led to the ongoing clinical testing of VCL-IM01 with EP 
in a phase I clinical trial (ClinicalTrials.gov ID NCT00223899). 
Thirty patients with metastatic melanoma are scheduled to receive 
VCL-IM01 at various dose concentrations intratumorally followed 
by EP using the Medpulser EPT System. The primary endpoint of 
the study is safety, with secondary outcomes including response 
rate, assessment of injected tumors for induration, inflammation, 
and erythema, and serum levels of IL-2. Tumor burden, response 
rate, and disease progression will also be assessed.
The success of the administration of plasmid IL-2 led to stud-
ies examining the potential of IL-12 in combination with EP in 
murine melanoma tumor models. A local antitumor effect with 
reduced systemic cytokine levels was observed.34 The combina-
tion of EP with either murine IL-2 or IL-12 plasmids resulted in a 
significant growth delay of ~5–15 days compared to control plas-
mid plus EP and the respective naked cytokine plasmids without 
EP.34 Further studies demonstrated that intratumoral injection of 
plasmid IL-12 with EP of mice with B16.F10 melanoma tumors 
resulted in 80% being tumor free for >100 days and resistant to 
challenge with B16 cells.35,36 To facilitate the translation of this 
approach to the clinic, toxicity was evaluated in the B16.F10 
melanoma model. Expression levels of IL-12 were significantly 
increased when delivered with EP in addition to complete regres-
sion of tumors, when plasmid IL-12 was delivered with EP, the 
findings showed minimal to no toxicity.37
The phase I trial of intratumoral pIL-12 EP in patients with 
Stage IIIB/c or IV malignant melanoma (n = 24) (ClinicalTrials.
gov ID NCT00323206) was designed to determine safety and tol-
erability, the correct dose of this type of treatment, and also its 
effectiveness in treating melanoma. EP was performed using the 
Medpulser EPT System. Primary outcome measures included 
 toxicity profile, maximum-tolerated dose, recommended dose for 
a phase II study, local and systemic response, and local and sys-
temic expression of IL-12 and IFN-γ. An increase in IL-12 and 
IFN-γ was observed locally within treated tumors but no increase 
in serum levels was seen. Biopsies of treated lesions revealed 
marked necrosis and lymphocytic infiltration. In addition, 8 of 
the 24 patients were observed to have stable disease and two of 
them had a complete response of all lesions, treated and untreated. 
This first human trial investigated IL-12 gene transfer utilizing 
in vivo DNA EP in metastatic melanoma and showed that it is 
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Figure 1 clinical trials using electroporation. (a) Seven gene therapy 
trials are listed on regulatory Web sites and investigate the benefits of 
EP; out of these, two are examining the tolerability of the technology. 
Five trials are investigating the combination of EP with nongene therapy 
approaches (anticancer drugs) for the treatment of cancer. One com-
pleted nongene therapy study by Merck tested the tolerability of EP 
in healthy adults. The number of trials is presented as a  percentage. 
(b) Conditions addressed by EP clinical trials. Four trials examining the 
potential of EP in the treatment of melanoma. For all other  conditions 
there is  presently just one trial. Five of the trials (one head and neck 
 cancer, one  melanoma, one pancreatic cancer, one breast cancer, and one 
cutaneous/ subcutaneous cancer) involve non-gene therapy approaches. 
The number of trials is presented as a percentage.
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The preclinical findings indicate that the application of cytok-
ines alone can improve efficacy but the addition of EP can fur-
ther enhance their therapeutic potential. The clinical trials will 
 hopefully demonstrate that the combination of EP with cytokine-
expressing plasmids will be effective in treating humans with 
melanoma.
Xenogeneic tyrosinase dnA vaccine
The tyrosinase family proteins are well-characterized differentia-
tion antigens recognized by antibodies and T cells of patients with 
melanoma. Preclinical mouse studies revealed that xenogeneic 
DNA vaccination with genes encoding tyrosinase family  members 
can induce antibody and cytotoxic T cell responses resulting in 
tumor rejection.39,40 The addition of EP for administration of 
plasmid encoding, a novel construct of autologous, melanocyte 
antigen tyrosinase–related protein-2, resulted in very high num-
bers of CD8+ T cells and significant delay in tumor growth after 
challenge in mice.41 These results led to the examination of the 
long-term survival of dogs with advanced spontaneous malignant 
melanoma after DNA vaccination with xenogeneic human tyro-
sinase in a single-arm phase I trial.42,43 Nine dogs were injected 
with human tyrosinase plasmid DNA intramuscularly (IM) via a 
 different methodology, using Biojector2000, a needle-free delivery 
device. The trial demonstrated that the vaccination was safe and 
efficacious. The median survival time for all vaccinated dogs was 
just over 1 year compared to dogs treated using historical controls 
with conventional therapies that survived 1–5 months. Antibody 
responses were documented in a follow-up publication, with three 
out of the nine dogs showing a response.44
Based on these encouraging results, a phase I trial of mouse 
and human TYR DNA vaccines in 18 stage-III/IV melanoma 
patients was conducted to assess safety and immunogenicity 
using the Biojector2000.45 This needle-free injection system was 
well tolerated and T cell responses were detected in seven patients. 
Median survival time had not been determined after >42 months 
follow-up, at the time of study publication. The results of this 
study and the advent of efficacious EP devices have led to the 
larger evaluation of various DNA delivery methods including a 
phase I clinical trial investigating the safety and immunogenicity 
of xenogeneic tyrosinase DNA vaccine, administered IM with EP 
to patients with stage IIB, IIC, III, or IV melanoma (ClinicalTrials.
gov ID NCT00471133). Primary outcome measures include 
table 1 clinical trial cases involving gene therapy and electroporation
nct or Gt Id Phase Status Sponsor condition Intervention Primary objective
NCT00223899 I Active, not recruiting Vical Metastatic 
Melanoma
Intratumoral VCL-IM01 
(encoding IL-2) with Inovio 
MedPulser device
Safety and efficacy, 
dose escalation
NCT00323206 I Recruiting H. Lee Moffitt Cancer Center 
and Research Institute; 




Intratumoral IL-12 pDNA with 
Inovio MedPulser device
Toxicity and efficacy, 
recommended dose 
for phase II study, 
local, and systemic 
response







Biological: Xenogeneic  
Tyrosinase DNA Vaccine;  




NCT00545987 I Active, not recruiting Rockefeller University; 
Aaron Diamond AIDS 
Research Center; Bill and 
Melinda Gates Foundation; 
Ichor Medical Systems 
Incorporated; International 
AIDS Vaccine Initiative
HIV Infections ADVAX DNA-based HIV  




NCT00685412 I Recruiting VGX Pharmaceuticals Inc. Papillomavirus  
Infections
Biological: VGX-3100 via EP 
using the CELLECTRA constant 
current device
Safety and tolerability 
of escalating doses
NCT00721461 I Completed Merck; University of 
California, San Diego; Inovio 
Biomedical Corporation
Healthy IM injection of phosphate- 
buffered saline solution Inovio 
MedPulser device
Tolerability of the 
MedPulser DNA 
delivery system
NCT00563173 I/II Recruiting Tripep AB; Inovio  
Biomedical Corporation
Chronic  
Hepatitis C Virus 
Infection
IM administered  
CHRONVAC-C in combination 
with Inovio MedPulser device
Safety, tolerability, 
and efficacy
UK-112 I/II Ongoing Cancer Research UK 
Oncology Unit,  
Southampton, UK
Prostate cancer Prostate-specific membrane 
antigen (PSMA)/pdom fusion 
gene, IM injection with or 
without Inovio MedPulser device
—
Abbreviations: EP, electroporation; IM, intramuscular.
Note: NCT ID Web site www.ClinicalTrials.gov (Clinical Trials.gov); GT ID Web site http://www.wiley.com/legacy/wileychi/genmed/clinical/ (gene therapy clinical 
trials worldwide).
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evaluation of the safety and feasibility of EP-mediated IM delivery 
and assessment of the magnitude and frequency of tyrosinase-spe-
cific immunologic responses in the immunized patients. Patients 
with measurable tumors will be assessed for evidence of antitu-
mor responses following immunization. The ability of xenogeneic 
 tyrosinase DNA vaccine in combination with EP will hopefully 
lead to even greater increases in immune responses, antitumor 
effects, and increased longevity compared to the vaccine alone.
HIv InFEctIonS
Since the identification of the causative agent of acquired immu-
nodeficiency syndrome (AIDS) in the early 1980s progress toward 
an effective vaccine has been hindered by the pathogenesis of the 
virus itself. Although current treatment with antiretroviral drugs 
can turn this fatal disease into a manageable chronic condition, 
the need for a novel therapeutic strategy is without question to 
control the AIDS pandemic.
Attempts at developing an effective AIDS vaccine led to 
the recent STEP AIDS vaccine study by Merck. The STEP HIV 
 vaccine trial used a modified recombinant adenovirus serotype 
5 (rAd5) as a vaccine vector along with three synthetically pro-
duced HIV genes (gag, pol, and nef).46 The phase I and phase II 
human clinical trials were suspended based on an interim data 
review that concluded that the vaccine could not be shown to pre-
vent HIV infection or reduce the amount of virus in those who 
became infected (ClinicalTrials.gov Identifier: NCT00486408 and 
NCT00413725). Further analysis of the study suggested that those 
participants who received the vaccine were more susceptible to 
HIV infection, especially those who had higher levels of preexist-
ing immunity (antibodies) to Ad5 due to prior natural exposure 
to that particular type of cold virus. (http://www3.niaid.nih.gov/
news/QA/step_qa.htm). Nevertheless, the lessons learned from 
these trials are invaluable, and establish the basis for the next 
 generation of vaccines.
One method to overcome the issue of preexisting immu-
nity, which was problematic in the STEP trial, is the use of DNA 
 vaccines in place of their viral counterparts. Numerous studies and 
clinical trials are examining the potential of DNA vaccines as HIV 
therapeutics. In a phase I trial, the safety and immunogenicity of 
a multigene, polyvalent HIV-1 DNA plasmid prime/Env protein–
boost vaccine formulation was evaluated in healthy volunteers 
(ClinicalTrials.gov Identifier: NCT00061243)  demonstrating 
T cell responses as well as high-titer serum antibody  responses.47 
The combination of a DNA vaccine with cytokines indicated 
that memory-immune responses in SIV-infected macaques were 
enhanced.48
Further studies have demonstrated that the route and dose of 
DNA vaccine is critical for optimal immune responses.49 Results 
of a phase I trial demonstrated that vaccination with a DNA prime 
formulation followed by a protein boost for seronegative adults 
induced HIV-1-specific T cells and anti-Env antibodies capable 
of neutralizing cross-clade viral isolates. Additional studies exam-
ined vaccination with a low dose of DNA administered intrader-
mic (ID) compared with low or high dose of DNA administered 
IM. Each group subsequently received one or two doses of the 
gp120 protein–boost vaccine IM. The high dose, administered 
IM, resulted in a greater response than ID after DNA vaccination. 
However, after the second protein boost, the magnitude of T cell 
responses in the ID group was indistinguishable from those in 
the other two groups. The need for a prime/boost strategy in this 
case was important for a quality immune response. In another 
phase I trial, patients who received four IM immunizations with 
a DNA vaccine did not differ statistically in rate of response from 
placebo controls.50 It would seem, therefore, that the route of 
administration and the dose are both extremely important for 
success. Nevertheless, other studies have shown that the efficacy 
of the prime/boost vaccination regime by needle injection can be 
improved and simplified by the use of EP.
Several studies have examined the potential of EP in the 
administration of a HIV vaccine. In mice, in vivo EP amplified 
cellular and humoral immune responses to a HIV type 1 Env DNA 
vaccine, enabled a tenfold reduction in vaccine dose, and resulted 
in an increased recruitment of inflammatory cells.51 Nonhuman 
primate studies examined four different administration strate-
gies, namely, DNA by IM injection, DNA with plasmid-encoded 
IL-12 by IM injection, DNA by IM injection with in vivo EP, and 
DNA with IL-12 by IM EP.52 Each group was immunized three 
times with optimized HIV gag and env constructs. The com-
bined approach of cytokine adjuvant and EP resulted in dramati-
cally higher cellular as well as humoral responses and a tenfold 
increase in antigen-specific IFN-γ(+) cells compared to IM DNA 
immunization. Further studies supporting these findings dem-
onstrated that an optimized HIV gag expression plasmid admin-
istered by EP resulted in an expansion of antigen-specific CD4+ 
and CD8+ T cells of both central and effector memory phenotype 
in SIV-infected animals.53 These studies all utilized the IM route 
of administration, but ID EP administration of an HIV DNA 
 vaccine in nonhuman primates has also been shown to be effec-
tive at inducing high-humoral and cellular-immune responses 
 compared to ID injection alone.54 Other studies show that EP of 
low-dose HIV env elicited Th1 cytokines and antienvelope anti-
bodies. The subsequent boosting of DNA-primed animals with 
gp120  proteins administered with either QS-21, or the orally 
administered immunomodulator, Talabostat, has been shown to 
augment cellular immune responses.55–57
The safety and immunogenicity of a plasmid HIV  vaccine, 
ADVAX env/gag + ADVAX pol/nef-tat (ADVAX), is being 
examined in an ongoing phase I trial in HIV uninfected 
adults (ClinicalTrials.gov Identifier: NCT00249106) and in 
 combination with EP as a potential protective vaccine against HIV 
(ClinicalTrials.gov Identifier: NCT00545987). The dual-promoter 
multigenic DNA vaccine capable of high-level expression of two 
independent transgenes was designed and constructed.58 HIV-1 
gag, pol, env, nef, and tat from a primary subtype C/B´ CCR5-
tropic HIV-1 were codon optimized and then modified to remove 
known functional activity, and assembled using an overlapping 
polymerase chain reaction into two plasmids, namely, ADVAX-I 
(containing env and gag) and ADVAX-II (containing pol and 
nef-tat). In this randomized, placebo-controlled, dose-escalating, 
double-blinded phase I study local and systemic reactogenicity 
signs and symptoms as well as adverse effects were investigated 
after the administration of one to three doses of ADVAX. This 
has led to the current study that is recruiting participants to test 
the safety and immunogenicity of an IM injection of two doses 
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of ADVAX using the EP TriGrid Delivery System (Ichor Medical 
Systems, ClinicalTrials.gov Identifier: NCT00545987). Of note, 
this trial is investigating the prophylactic potential of a DNA 
 vaccine  administered by EP and is part of a broader research effort 
to determine whether changes in the way vaccines are adminis-
tered can make them more effective.
HuMAn PAPIlloMAvIruS InFEctIonS
Human papillomavirus (HPV) infection is the major cause of 
 cervical cancer. Although the recently FDA-approved HPV 
 vaccine Gardasil has been shown to prevent infection, it does not 
provide treatment for individuals already infected. Therefore, the 
development of a therapeutic HPV vaccine is of great importance. 
The HPV genome encodes two HPV late genes, L1 and L2, which 
form the viral capsid. Early viral proteins support viral genome 
replication, two of which (E6 and E7) are important for HPV-
associated malignant transformation. Prophylactic vaccines target 
the HPV capsid protein L1, thereby preventing infection, whereas 
therapeutic HPV vaccines target the E6 and E7 proteins.59
Studies have demonstrated that DNA vaccines can induce 
CTL responses and antitumor activity. Administration of a codon-
 optimized HPV-16 E6 DNA vaccine (pNGVL4a-E6/opt) resulted 
in significantly enhanced E6-specific CD8+ T cell immune 
responses in mice. Protective and therapeutic antitumor effects 
were also noted against challenge.60 Other groups report that a 
DNA vaccine–encoding calreticulin (CRT) linked to HPV-16 E7 
generated potent E7-specific CD8+ T cell-immune responses and 
antitumor effects against an E7-expressing tumor.61 Furthermore, 
development of a similar DNA vaccine encoding CRT linked to 
E6 (CRT/E6) generated significant T cell responses and could 
 protect mice from challenge.62
An earlier study utilized the technique of EP for the intro-
duction of plasmids that express antisense RNA of the E6 and 
E7 genes on the growth of HPV positive human cancer cell lines 
resulting in slowed growth.63 Several other studies are examin-
ing the potential of EP for administration of dendritic cell–based 
tumor vaccines.64,65
Strong cellular immune responses can be induced in both mice 
and nonhuman primates following the administration with EP of 
a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus 
protein.66 These finding have lead to a phase I study using a DNA 
vaccine, VGX-3100, which includes plasmids targeting E6 and E7 
proteins of both HPV subtypes 16 and 18 that will be  delivered 
using the constant current CELLECTRA EP device following 
IM injection (ClinicalTrials.gov identifier: NCT00685412). This 
study will determine the dose, safety, and tolerability as well as 
the humoral and cellular immune responses in adult female sub-
jects’ postsurgical or ablative treatment of grade 2 or 3 cervical 
 intraepithelial neoplasia.
HEPAtItIS c
Hepatitis C is a blood-borne infectious disease that is caused by 
hepatitis C virus (HCV) infecting hepatocytes with almost one 
third of infected individuals progressing to liver disease. No 
 vaccine against hepatitis C is available and current treatment 
strategies are insufficiently effective, poorly tolerated, and expen-
sive. A DNA vaccine encoding cell-surface HCV-envelope 2 (E2) 
glycoprotein was shown to stimulate strong immune responses in 
mice and rhesus macaques. Immunization of chimpanzees did not 
result in protection from challenge but prevented progression to a 
chronic state.67 Therefore, the development of novel vaccines and 
delivery methods will be important in treating this highly preva-
lent infection.
To this end, a synthetic nonstructural (NS) NS3/4A-based 
DNA vaccine was generated in which the codon usage was opti-
mized for human cells.68 In a study examining the in vivo EP of 
the HCV NS3/4A DNA vaccine revealed increased and prolonged 
expression of protein levels as well as an increased infiltration 
of CD3+ T cells at the site of injection, likely contributing to an 
observed enhancement of CD4+ T cells, CD8+ T cells, and IFN-γ 
production. The increase in CD8+ T cells resulted in the elimina-
tion of HCV NS3/4A-expressing liver cells in transiently trans-
genic mice.69 In a separate study, a construct encoding a HCV 
genotype 1a/1b consensus immunogen of proteins NS3/4A was 
used to immunize mice followed by IM EP. Results show that 
strong anti-NS3/4A T cell responses in mice as well as in rhesus 
macaques were induced.70 In mice and nonhuman primates, EP of 
a DNA vaccine encoding an optimized version of the NS region of 
HCV (from NS3 to NS5B) induced strong and long-lasting CD4+ 
and CD8+ cellular immunity compared to naked DNA injection 
alone.71 Furthermore, in the same study, vaccination with EP pro-
duced a higher CD4+ T cell response than an adenovirus 6-based 
viral vector encoding the same antigen.
Currently, there is one clinical trial evaluating the administra-
tion of the DNA vaccine CHRONVAC-C by IM injection with EP 
using the Inovio Elgen system. CHRONVAC is a therapeutic vac-
cine given to individuals already infected with HCV. Early results 
indicate that the first two patients given the intermediate dose 
of CHRONVAC-C with EP had reduced viral loads (by 87 and 
98%) and that there may be a dose-dependent correlation between 
T cell responses generated and reduction in hepatitis C viral 
load. No severe adverse effects have been noted (http:// tripep.se/ 
english/news/press_releases/?id=2008063020130). These findings 
are extremely promising for the continued development of DNA 
vaccines and the use of EP for treatment of hepatitis C.
ProStAtE cAncEr
Prostate cancer is one of the most common types of cancer in 
men. Treatment options for prostate cancer are primarily surgery 
and radiation therapy; however, statistical data point that 186,320 
men will be diagnosed with cancer of the prostate and 28,660 men 
will die due to this cancer in 2008 (http://seer.cancer.gov/statfacts/
html/prost.html). Prostate-specific antigen (PSA) is a serine pro-
tease secreted at high levels by prostate cancer cells making it a 
potential target for immunotherapeutic approaches.
DNA-based vaccines have been shown to induce CTLs specific 
for prostate antigens. A phase I clinical trial previously revealed 
that vaccination with a PSA DNA vaccine in patients with pros-
tate cancer is safe and can induce cellular and humoral immune 
responses against PSA protein.72,73 The technique of EP has been 
investigated as a more effective way for delivering PSA DNA 
vaccines.74,75 In mice, the ID EP of a prostate cancer DNA vac-
cine encoding PSA resulted in 100- to 1,000-fold increased gene 
expression and higher levels of PSA-specific T cells, compared to 
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DNA delivery alone.75 Further investigations demonstrated that 
ID DNA vaccination with small amounts of DNA followed by two 
sets of electrical pulses of different length and voltage, effectively 
induced PSA-specific T cells.74
Currently, there is one clinical trial examining the ability of EP 
to enhance the effectiveness of vaccination against prostate cancer. 
Interim data from the clinical study suggest that the treatment is 
safe and well tolerated and that higher levels of antibody as well 
as CD4+ and CD8+ T cells were detected in patients treated with 
EP. Tolerability of the procedure was also documented in this trial. 
Patients were given a choice between simple IM vaccination and 
repeat EP—all patients chose repeat EP. The heightened immune 
responses in patients treated using EP further validate the  efficacy 
of this DNA vaccine delivery method (http://www.medical-
newstoday.com/articles/102919.php).
PrEclInIcAl APPlIcAtIonS oF EP For FuturE 
clInIcAl uSE
There are several preclinical studies that have investigated EP 
but have not yet made it to the clinical trial stage. The injection 
of plasmid DNA in the retina with and without EP in vivo and 
in vitro was carried out in rodents. Appropriate expression pat-
terns and long-term expression of the constructs carrying reti-
nal cell type–specific promoters was observed.76,77 The retina is 
an  interesting target system for the study of neural development 
and treatment of disease and is being pursued for transition to 
humans. Another promising area is that of inflammatory disease, 
in particular  rheumatoid arthritis, where EP of plasmids encoding 
for human tumor necrosis factor alpha–soluble receptor I variants 
(hTNFR-Is) were shown to exert protective effects, with decreased 
joint destruction in the ankles.78
Other studies are investigating the use of EP for vaccina-
tion against influenza virus. An optimized H5N1 hemagglutinin 
(HA)-based DNA vaccine administered by IM EP was shown to 
elicit antibodies that neutralized a panel of virions from various 
H5N1 viruses and protected the immunized mice from H5N1 
virus  challenges.79 In a separate study mice, ferrets and nonhu-
man primates were immunized by combining several consen-
sus influenza antigens with in vivo EP inducing both protective 
 cellular and humoral immune responses. Furthermore, in a ferret-
 challenge model, vaccination with EP protected against morbid-
ity and  mortality.80 The continued development and transition 
to clinical trial status of such research will be important for the 
expansion and success of DNA vaccination with EP.
SuMMAry
This review demonstrates the wide-reaching ability of DNA deliv-
ery with EP to treat or prevent numerous diseases. The contin-
ued research into this approach will enable this technology to be 
applied to many more conditions that are lacking effective thera-
pies. Recently, the technique of EP itself, independent of DNA 
delivery, has been shown to recruit and trigger cells involved in 
antigen presentation and immune response.81 Therefore, EP has 
adjuvant-like properties that will enhance the continued develop-
ment and success of DNA vaccines and immunotherapeutics. The 
results from the current phase I studies will provide important 
safety information as well as preliminary efficacy data in humans 
for EP-assisted delivery of plasmid DNA enabling the transition to 
phase II and III studies and ultimately for use in clinical practice. 
Interim data from some of the current clinical trials as discussed 
suggest that the technique of EP for the administration of DNA 
vaccines and immunotherapies is a powerful tool for combating 
diseases. Not only does EP enhance humoral and cellular immune 
responses, but it also decreases injection volume, minimizes the 
number of applications, and prolongs the vaccine or therapeutic 
effects. The route of administration will also likely play a large 
role in the transition of EP to humans. Although most preclinical 
studies to date have centered on IM applications, the ID route of 
application will likely be more readily accepted by the majority 
of the population. Together with the fact that skin administration 
has been the status quo for vaccinations, the ease of accessibil-
ity and the reduced pain level compared to IM injections may 
increase public acceptance. Evolution of the EP device itself from 
a lab-like instrument to an esthetically pleasing, biosafe medical 
tool that is easily operated and portable with low-cost disposables 
will also be necessary for its future widespread use. Therefore, the 
further development and application of EP will be of significant 
 importance in administration of vaccines to the public, in terms 
of compliance and economical feasibility.
The most current developments in the field of EP are targeted 
toward therapeutic applications. However, the one ongoing pro-
phylactic vaccine study and many preclinical studies targeted to 
prophylaxis suggest that using EP technology for prophylactic 
applications may be feasible, depending on application, safety, and 
tolerability data. Overall, the further understanding and develop-
ment of EP will play an important role in advancing the use of 
DNA vaccinations as well as the administration of DNA-based 
immunotherapies or other therapeutic approaches.
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